Neurofibromatosis type 1 and optic pathway glioma: Molecular interplay and therapeutic insights

Children with neurofibromatosis type 1 (NF1) are predisposed to develop central nervous system neoplasms, the most common of which are low‐grade gliomas (LGGs). The absence of human NF1 associated LGG‐derived cell lines, coupled with an inability to generate patient‐derived xenograft models, represents barriers to profile molecularly targeted therapies for these tumors. Thus, genetically engineered mouse models have been identified to evaluate the interplay between Nf1‐deficient tumor cells and nonneoplastic stromal cells to evaluate potential therapies for these neoplasms. Future treatments might also consider targeting the nonneoplastic cells in NF1–LGGs to reduce tumor growth and neurologic morbidity in affected children.